Search PubMed⌕ Search

Biomedical subjects

E Caballero

Publications and source records attributed to E Caballero.

At least 55 records · Page 3Linked to original sources
PubMed1995

[Extracorporeal lithotripsy: comparative study with magnetic resonance, ultrasonography, and nuclear medicine of short-term renal changes produced by piezoelectric and electrohydraulic equipment].

Ultrasound, Nuclear Magnetic Resonance (NMR) and Nuclear Medicine (NM) were used to evaluate short-term changes and renal complications (within the first 10 days) induced by extracorporeal lithotrity (ESWL) from two separate lithotripters. To this end, a consecutive prospective study with 18 randomly selected patients, all candidates to ESWL, was conducted. ESWL was performed using a piezoelectric lithotripter in 10 patients and an electrohydraulic equipment in 8 patients. Qualitative evaluation of images was done with ultrasound and NMR (changes in renal morphology: shape, cortico-medullary definition, size, changes in perirenal space), and with isotopic renogram (global renal function); while quantitative evaluation was done with NMR (measurement of signal intensity on cortex, marrow and muscle), and with isotopic renogram (semiquantitative assessment of unilateral renal function and renal excretory function). ESWL with piezoelectric and electrohydraulic lithotripter shows a low short-term complication rate: changes of cortico-medullary differentiation (ultrasound in 27.8% cases, NMR in 5.6%) and perirenal striations (NMR in 11%). No renal function changes were found. These observations have not been quantitatively corroborated; we have not found statistically significant differences between changes produced after ESWL either with piezoelectric or electrohydraulic lithotripters.

Female↗
PubMed1989

[Spanish talcs for pharmaceutical use. Mineralogic, chemical composition, physico-chemical properties].

A study has been carried out on the possible pharmaceutical use of 4 spanish talcs by direct estimation of the mineral purity by means of X-ray diffraction techniques, chemical analysis and quantification of some physico-chemical properties. There is a high level of talc in the samples 2 and 4, except in the talc 1 and the talc 3, with a relatively high content of chlorides. Quartz, calcite, feldspar, smectite, inter-stratified phases, kaolinite, amphibole, muscovite and dolomite are other contaminating minerals. The negative effects of these minerals on the pharmaceutical use of the talc include changes in the physical properties (colour), in the chemical ones (contained in heavy metals) as well as in the physico-chemical ones (adsorption properties). The data concerning cation exchange capacity and total specific surface are slightly higher than those concerning the pure mineral, and this is due to the occurrence of some contaminating minerals.

Chemistry, Pharmaceutical↗
PubMed1983

Identification of lactaldehyde dehydrogenase and glycolaldehyde dehydrogenase as functions of the same protein in Escherichia coli.

Lactaldehyde dehydrogenase is an enzyme involved in the aerobic metabolism of fucose in wild type Escherichia coli, and glycolaldehyde dehydrogenase is an enzyme involved in the metabolism of ethylene glycol in mutant cells able to utilize this glycol. Both enzyme sources display oxidative activity on either substrate with a constant ratio between these activities. We have found that both enzymatic activities present the same electrophoretic mobility when crude extracts were electrophoresed in polyacrylamide gels and the gels stained for enzyme activities. Furthermore, both enzymatic activities co-chromatograph in a DEAE-Sephadex column. If lactaldehyde dehydrogenase of wild type cells is purified near homogeneity and the purification procedure is screened for both aldehydes as substrates, only one enzyme is apparent, giving again a constant ratio between lactaldehyde and glycolaldehyde dehydrogenase activities. Genetic evidence of the fact that both activities are functions of the same protein is provided by the observation that mutation to thermosensitivity for the production of lactaldehyde dehydrogenase affected in the same way the production of glycolaldehyde dehydrogenase. Glycolaldehyde dehydrogenase from mutant cells is purified in a procedure coincident with the lactaldehyde dehydrogenase purification, yielding a single enzyme electrophoretically indistinguishable from the purified lactaldehyde dehydrogenase. Peptide mapping of the purified preparation after digestion with chymotrypsin or Staphylococcus aureus protease V8 gives an indistinguishable band pattern between both enzymes.

Aldehyde Oxidoreductases↗
PubMed1983

Experimental evolution of a metabolic pathway for ethylene glycol utilization by Escherichia coli.

Spontaneous mutants of Escherichia coli able to grow on ethylene glycol as a sole source of carbon and energy were obtained from mutants that could grow on propylene glycol. Attempts to obtain ethylene glycol-utilizing mutants from wild-type E. coli were unsuccessful. The two major characteristics of the ethylene glycol-utilizing mutants were (i) increased activities of propanediol oxidoreductase, an enzyme present in the parental strain (a propylene glycol-positive strain), which also converted ethylene glycol into glycolaldehyde; and (ii) constitutive synthesis of high activities of glycolaldehyde dehydrogenase, which converted glycolaldehyde to glycolate. Glycolate was metabolized via the glycolate pathway, which was present in the wild-type cells; this was indicated by the induction in ethylene glycol-grown cells of glycolate oxidase, the first enzyme in the pathway. Glycolaldehyde dehydrogenase was partially characterized as an enzyme of this new metabolic pathway in E. coli, and glycolate was identified as the product of the reaction. This enzyme used NAD and NADP as coenzymes, although the NADP-dependent activity was about 10 times lower than the NAD-dependent activity. Uptake of [14C]ethylene glycol was dependent on the presence of the enzymes capable of metabolism of ethylene glycol. Glycolaldehyde and glycolate were identified as intermediate metabolites in the pathway.

Acetaldehyde↗
PubMedDate not supplied

[Irbesartan].

Explore the source record for details and available documents.

Angiotensin II↗
PubMedDate not supplied

[Moxifloxacin].

Explore the source record for details and available documents.

Anti-Infective Agents↗